{"id":"dhfr","name":"Dihydrofolate reductase (DHFR)","symbol":"DHFR","route":"/targets/dhfr/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2861","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000228716","uniprot":"https://www.uniprot.org/uniprotkb/P00374/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P00374","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL202","open-targets":"https://platform.opentargets.org/target/ENSG00000228716","civic":"https://civicdb.org/genes/1719/summary","oncokb":"https://www.oncokb.org/gene/DHFR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DHFR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=DHFR","depmap":"https://depmap.org/portal/gene/DHFR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000228716-DHFR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1719","omim":"https://www.omim.org/entry/126060"}],"products":[{"id":"aminopterin","name":"Aminopterin","status":"historic","modality":"Antifolate (historic)","route":"/drugs/aminopterin/"},{"id":"leucovorin","name":"Leucovorin (folinic acid)","status":"established","modality":"Reduced folate (rescue agent and chemotherapy modulator)","route":"/drugs/leucovorin/"}],"trials":[{"id":"nct04094688","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","nct":"NCT04094688","phase":"3","status":"active"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"esopec","name":"ESOPEC","nct":"NCT02509286","phase":"3","status":"positive"},{"id":"prodige-7","name":"PRODIGE 7","nct":"NCT00769405","phase":"3","status":"negative"},{"id":"abc-06","name":"ABC-06","nct":"NCT01926236","phase":"3","status":"positive"},{"id":"nct00557193","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","nct":"NCT00557193","phase":"3","status":"completed"},{"id":"napoli-1","name":"NAPOLI-1","nct":"NCT01494506","phase":"3","status":"positive"},{"id":"conko-003","name":"CONKO-003 (OFF)","nct":"NCT00786058","phase":"3","status":"positive"},{"id":"eortc-40983","name":"EORTC 40983","nct":"NCT00006479","phase":"3","status":"mixed"},{"id":"nct00399035","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","nct":"NCT00399035","phase":"3","status":"completed"},{"id":"prodige-4-accord-11","name":"PRODIGE 4 / ACCORD 11","nct":"NCT00112658","phase":"3","status":"positive"},{"id":"espac-3","name":"ESPAC-3","nct":"NCT00058201","phase":"3","status":"completed"},{"id":"petacc-3","name":"PETACC-3","nct":"NCT00026273","phase":"3","status":"negative"},{"id":"quasar","name":"QUASAR","nct":"ISRCTN82375386","phase":"3","status":"positive"},{"id":"avf2107g","name":"AVF2107g","phase":"3","status":"positive"},{"id":"espac-1","name":"ESPAC-1","phase":"3","status":"mixed"},{"id":"mosaic","name":"MOSAIC","nct":"NCT00275210","phase":"3","status":"positive"},{"id":"netherlands-hipec","name":"Netherlands Cancer Institute HIPEC trial","phase":"3","status":"positive"},{"id":"int-0116","name":"INT-0116 (Macdonald trial)","phase":"3","status":"positive"},{"id":"nct06750094","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","nct":"NCT06750094","phase":"3","status":"recruiting"},{"id":"nct06662786","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","nct":"NCT06662786","phase":"3","status":"recruiting"},{"id":"nct06901531","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","nct":"NCT06901531","phase":"3","status":"recruiting"},{"id":"ballad","name":"BALLAD","nct":"NCT02502370","phase":"3","status":"active"},{"id":"nct03678428","name":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","nct":"NCT03678428","phase":"3"},{"id":"nct06217042","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","nct":"NCT06217042","phase":"3","status":"planned"},{"id":"nct07238283","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","nct":"NCT07238283","phase":"3","status":"recruiting"},{"id":"nct04919226","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","nct":"NCT04919226","phase":"3","status":"active"},{"id":"nct07412613","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","nct":"NCT07412613","phase":"3","status":"recruiting"},{"id":"nct00002893","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","nct":"NCT00002893","phase":"3"},{"id":"nct07271355","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","nct":"NCT07271355","phase":"3","status":"planned"},{"id":"nct07775287","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","nct":"NCT07775287","phase":"3","status":"recruiting"},{"id":"nct07621718","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","nct":"NCT07621718","phase":"3","status":"recruiting"},{"id":"nct02885753","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","nct":"NCT02885753","phase":"3","status":"recruiting"},{"id":"nct00660894","name":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","nct":"NCT00660894","phase":"3","status":"completed"},{"id":"nct06958328","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","nct":"NCT06958328","phase":"3","status":"recruiting"},{"id":"nct05863195","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","nct":"NCT05863195","phase":"3","status":"recruiting"},{"id":"nct06490536","name":"The Sagittarius Trial","nct":"NCT06490536","phase":"3","status":"recruiting"},{"id":"flot4","name":"FLOT4-AIO","nct":"NCT01216644","phase":"2/3","status":"positive"},{"id":"nct07585279","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","nct":"NCT07585279","phase":"2/3","status":"planned"},{"id":"nct06662877","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","nct":"NCT06662877","phase":"2/3","status":"planned"},{"id":"nct04068103","name":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","nct":"NCT04068103","phase":"2/3","status":"active"},{"id":"nct05610163","name":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage","nct":"NCT05610163","phase":"2/3","status":"active"},{"id":"naliricc","name":"NALIRICC (AIO)","nct":"NCT03043547","phase":"2","status":"negative"},{"id":"nifty","name":"NIFTY","nct":"NCT03524508","phase":"2","status":"positive"},{"id":"panoptimox-prodige-35","name":"PANOPTIMOX-PRODIGE 35","nct":"NCT02352337","phase":"2","status":"completed"},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","nct":"NCT00057811","phase":"2","status":"completed"},{"id":"nct06887218","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","nct":"NCT06887218","phase":"2","status":"recruiting"},{"id":"nct06493760","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","nct":"NCT06493760","phase":"2","status":"recruiting"},{"id":"nct05859750","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","nct":"NCT05859750","phase":"2","status":"recruiting"},{"id":"nct03505320","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","nct":"NCT03505320","phase":"2","status":"active"},{"id":"nct07123441","name":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","nct":"NCT07123441","phase":"2","status":"planned"},{"id":"nct07441369","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","nct":"NCT07441369","phase":"2","status":"recruiting"},{"id":"nct06531278","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","nct":"NCT06531278","phase":"2","status":"recruiting"},{"id":"nct06438822","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","nct":"NCT06438822","phase":"2","status":"recruiting"},{"id":"nct00628810","name":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","nct":"NCT00628810","phase":"2","status":"completed"},{"id":"combomatch-binimetinib-folfox","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","nct":"NCT05564403","phase":"2","status":"active"},{"id":"nct06643793","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","nct":"NCT06643793","phase":"2","status":"recruiting"},{"id":"nct06780787","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","nct":"NCT06780787","phase":"2","status":"recruiting"},{"id":"nct07621497","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","nct":"NCT07621497","phase":"2","status":"planned"},{"id":"nct00541125","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","nct":"NCT00541125","phase":"2","status":"completed"},{"id":"nct00634322","name":"High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma","nct":"NCT00634322","phase":"2"},{"id":"nct06383078","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","nct":"NCT06383078","phase":"2","status":"planned"},{"id":"nct06928584","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","nct":"NCT06928584","phase":"2","status":"recruiting"},{"id":"nct06172036","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","nct":"NCT06172036","phase":"2","status":"planned"},{"id":"nct06184698","name":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","nct":"NCT06184698","phase":"2","status":"recruiting"},{"id":"nct07797816","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","nct":"NCT07797816","phase":"2","status":"recruiting"},{"id":"nct07062536","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","nct":"NCT07062536","phase":"2","status":"recruiting"},{"id":"nct04005339","name":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","nct":"NCT04005339","phase":"2","status":"active"},{"id":"nct06941857","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","nct":"NCT06941857","phase":"2","status":"recruiting"},{"id":"nife","name":"NIFE (AIO-YMO HEP-0315)","nct":"NCT03044587","phase":"2","status":"completed"},{"id":"nct06210360","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","nct":"NCT06210360","phase":"2","status":"planned"},{"id":"nct06341296","name":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","nct":"NCT06341296","phase":"2","status":"recruiting"},{"id":"nct07150403","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","nct":"NCT07150403","phase":"2","status":"planned"},{"id":"nct07025174","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","nct":"NCT07025174","phase":"2","status":"recruiting"},{"id":"nct07831993","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","nct":"NCT07831993","phase":"2","status":"recruiting"},{"id":"nct06107413","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","nct":"NCT06107413","phase":"2","status":"active"},{"id":"nct05628038","name":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","nct":"NCT05628038","phase":"2","status":"recruiting"},{"id":"nct02022358","name":"Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?","nct":"NCT02022358","phase":"2"},{"id":"nct05846867","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","nct":"NCT05846867","phase":"1/2","status":"active"},{"id":"nct07737600","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","nct":"NCT07737600","phase":"1/2","status":"planned"},{"id":"nct06703177","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","nct":"NCT06703177","phase":"1/2","status":"recruiting"},{"id":"nct04421820","name":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","nct":"NCT04421820","phase":"1/2","status":"recruiting"},{"id":"nct07705919","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","nct":"NCT07705919","phase":"1/2","status":"planned"},{"id":"nct07056777","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","nct":"NCT07056777","phase":"1/2","status":"recruiting"},{"id":"nct06782685","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","nct":"NCT06782685","phase":"1/2","status":"recruiting"},{"id":"nct07214298","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","nct":"NCT07214298","phase":"1/2","status":"recruiting"},{"id":"nct05647122","name":"First in Human Study of AZD9592 in Solid Tumors","nct":"NCT05647122","phase":"1","status":"active"}],"pathways":[],"companies":[],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}